Related Experiment Videos
[Growth suppression of squamous cell carcinoma cell lines by PKCs--possible application to gene therapy]
1Second Department of Oral Surgery, Faculty of Dentistry, Tokyo Medical and Dental University.
Abstract:
Protein kinase C is a serine/threonine kinase protein, which consists of 12 isoforms. Among these isoforms, PKC eta is known to play an important role in epithelial differentiation. The present study was conducted to examine the possibility that the introduction of these genes causes growth suppression of squamous cell carcinoma. It was found that adenovirus vectors containing cDNA of PKC eta suppresses the cell growth of human oral mucosal keratinocytes and activates transglutaminase 1, a key enzyme of squamous cell differentiation. In an oral squamous cell carcinoma cell line, overexpression of this isoform did not suppress the growth, but TPA treatment resulted in suppression of cell proliferation. A dominant negative form of PKC eta did not suppress the growth of carcinoma cell lines even with TPA-treatment. Human fibroblasts showed no response to TPA-treatment. The same result was shown with PKC delta. The results of this study suggested the possibility of using PKC isoforms for gene therapy.
Insights
Protein kinase C eta (PKC eta) gene therapy shows potential for treating squamous cell carcinoma by suppressing cancer cell growth. This research explores PKC isoforms for novel gene therapy applications in oncology.
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Context:
- Protein kinase C (PKC) comprises 12 isoforms, with PKC eta implicated in epithelial differentiation.
- Squamous cell carcinoma (SCC) presents a significant challenge in cancer treatment.
- Gene therapy offers a promising avenue for targeted cancer interventions.
Purpose:
- To investigate the potential of introducing PKC eta genes for growth suppression in squamous cell carcinoma.
- To explore the role of PKC eta in regulating oral mucosal keratinocytes and squamous cell differentiation.
- To assess the therapeutic efficacy of PKC isoforms in cancer treatment.
Summary:
- Adenovirus-mediated delivery of PKC eta cDNA suppressed human oral mucosal keratinocyte growth and activated transglutaminase 1, a marker of squamous differentiation.
- Overexpression of PKC eta did not inhibit oral SCC cell growth, but TPA treatment induced proliferation suppression.
- Dominant-negative PKC eta and PKC delta showed no growth suppression in carcinoma cells, even with TPA treatment.
Impact:
- The study suggests that PKC isoforms, particularly PKC eta, hold therapeutic potential for gene therapy in squamous cell carcinoma.
- Findings provide a basis for developing novel targeted therapies for SCC by modulating PKC signaling pathways.
- This research opens possibilities for utilizing specific PKC isoforms in future cancer treatment strategies.